Evidence map›Paper›PMID 30353882›Full record

ReviewInternational journal of radiation oncology, biology, physics2018

The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols.

Thomas J FitzGerald, Maryann Bishop-Jodoin, Fran Laurie, Elizabeth O'Meara, Christine Davis, Jeffrey Bogart, John Kalapurakal, Marilyn J Siegel, Bapsi Chakravarthy, Paul Okunieff and 13 more

Open access · greenAbstract readReview
In one paragraph

Review in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 1 country.

Thomas J FitzGeraldImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Lincoln, Rhode Island. Electronic address: TJFitzgerald@qarc.org.
Maryann Bishop-JodoinImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Lincoln, Rhode Island.
Fran LaurieImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Lincoln, Rhode Island.
Elizabeth O'MearaImaging and Radiation Oncology Core RT QA Center Philadelphia, American College of Radiology Center for Research, Philadelphia, Pennsylvania.
Christine DavisImaging and Radiation Oncology Core RT QA Center Philadelphia, American College of Radiology Center for Research, Philadelphia, Pennsylvania.
Jeffrey BogartAlliance for Clinical Trials in Oncology, State University of New York Upstate Medical University, Syracuse, New York.
John KalapurakalChildren's Oncology Group, Northwestern Medicine, Chicago, Illinois.
Marilyn J SiegelChildren's Oncology Group, Northwestern Medicine, Chicago, Illinois.
Bapsi ChakravarthyECOG-ACRIN Cancer Research Group, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Paul OkunieffSWOG, Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida.
Bruce HafftyDepartment of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, New Jersey Medical School and Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Jeff MichalskiDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Kenneth UlinImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Lincoln, Rhode Island.
David S FollowillImaging and Radiation Oncology Core QA Center Houston, MD Anderson Cancer Center, Houston, Texas.
Stephen KryImaging and Radiation Oncology Core QA Center Houston, MD Anderson Cancer Center, Houston, Texas.
Michael KnoppImaging and Radiation Oncology Core QA Center Ohio, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.
Jun ZhangImaging and Radiation Oncology Core QA Center Ohio, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio.
Don RosenImaging and Radiation Oncology Core RT QA Center Philadelphia, American College of Radiology Center for Research, Philadelphia, Pennsylvania.
Mark RosenImaging and Radiation Oncology Core RT QA Center Philadelphia, American College of Radiology Center for Research, Philadelphia, Pennsylvania.
Ying XiaoImaging and Radiation Oncology Core RT QA Center Philadelphia, American College of Radiology Center for Research, Philadelphia, Pennsylvania.
Lawrence SchwartzSWOG and Alliance for Clinical Trials in Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Janaki MoniImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Lincoln, Rhode Island.
Maria Giulia CicchettiImaging and Radiation Oncology Core QA Center Rhode Island, University of Massachusetts Medical School, Lincoln, Rhode Island.
University of Massachusetts Chan Medical School · USAmerican College of Radiology · USThe Ohio State University Wexner Medical Center · USThe University of Texas MD Anderson Cancer Center · USChildren's Oncology Group · USColumbia University Irving Medical Center · USECOG-ACRIN Cancer Research Group · USFlorida College · USNorthwestern Medicine · USRutgers Cancer Institute of New JerseySUNY Upstate Medical University · USWashington University in St. Louis · US

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
IROC: Enhancing local enrolling site radiological data capture capabilities for NCTN trialsU24CA180803 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Thomas J. FitzGerald, MICHAEL V KNOPP · 2014 to 2026
$116.2M
Washington University/ Siteman Cancer Center Lead Academic SiteU10CA180833 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L, KOZOWER, BENJAMIN D · 2014 to 2018
$7.6M
NCI National Clinical Trials Network - Lead Academic Participating SiteUG1CA233324 · NCI · UNIVERSITY OF COLORADO DENVER · PI ANTHONY D ELIAS · 2019 to 2026
$5.2M
Vanderbilt Network Lead Academic Participating Site for the NCTNUG1CA233270 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kristen Keon Ciombor · 2019 to 2026
$3.5M
NCI NIH HHS U10 CA180833NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA180803NCI NIH HHS UG1 CA233270NCI NIH HHS UG1 CA233324
6 · The paper itself

Abstract

Imaging is essential in successfully executing radiation therapy (RT) in oncology clinical trials. As technically sophisticated diagnostic imaging and RT were incorporated into trials, quality assurance in the National Clinical Trials Network groups entered a new era promoting image acquisition and review. Most trials involving RT require pre- and post-therapy imaging for target validation and outcome assessment. The increasing real-time (before and during therapy) imaging and RT object reviews are to ensure compliance with trial objectives. Objects easily transmit digitally for review from anywhere in the world. Physician interpretation of imaging and image application to RT treatment plans is essential for optimal trial execution. Imaging and RT data sets are used to credential RT sites to confirm investigator and institutional ability to meet trial target volume delineation and delivery requirements. Real-time imaging and RT object reviews can be performed multiple times during a trial to assess response to therapy and application of RT objects. This process has matured into an effective data management mechanism. When necessary, site and study investigators review objects together through web media technologies to ensure the patient is enrolled on the appropriate trial and the intended RT is planned and executed in a trial-compliant manner. Real-time imaging review makes sure: (1) the patient is entered and eligible for the trial, (2) the patient meets trial-specific adaptive therapy requirements, if applicable, and (3) the intended RT is according to trial guidelines. This review ensures the study population is uniform and the results are believable and can be applied to clinical practice.

Indexed as

Clinical ProtocolsClinical Trials as TopicHumansNeoplasmsQuality Assurance, Health CareRadiation Oncology

Identifiers

PMID30353882
PMCPMC6510266
OpenAlexW2896079040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.